<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ARBINOXA- carbinoxamine maleate solution </strong><br>Hawthorn Pharmaceuticals, Inc.<br></p></div>
<h1>Arbinoxa<span class="Sup">®</span> (Carbinoxamine Maleate) Oral Solution<br> [Hawthorn Pharmaceuticals, Inc]<br> Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Carbinoxamine maleate is a histamine-H<span class="Sub">1</span> receptor blocking agent.</p>
<p>Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate (hydrous) and sorbitol solution.</p>
<p>Carbinoxamine maleate is freely soluble in water. Its structure is:</p>
<p><img alt="Arbinoxa structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=040d6792-21fe-44cc-a441-b9693178b3b5&amp;name=f9ebe04a-39e2-4cfe-81d7-a692801dc334-01.jpg"></p>
<p> 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-<span class="Italics">N</span>, N-<span class="Italics">dimethylethanamine</span> (Z)-2-butenedioate (1:1)<br> C<span class="Sub">16</span>H<span class="Sub">19</span>ClN<span class="Sub">2</span>O•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span><br> MW = 406.86</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Carbinoxamine maleate is an antihistamine with anticholinergic (drying) and sedative properties. Antihistamines appear to compete with histamine for receptor sites on effector cells.</p>
<p>The pharmacological effects of carbinoxamine maleate after oral absorption have been shown to last approximately 4 hours.</p>
<p>Interactions of carbinoxamine maleate with food or with other drugs and the possibility of cardiac conduction effects on the QT interval have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_s3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carbinoxamine maleate is effective for the symptomatic treatment of:<br>Seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4305500" conceptname="Vasomotor rhinitis">Vasomotor rhinitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span> due to inhalant allergens and foods.</p>
<p>Mild, uncomplicated allergic skin manifestations of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>Dermatographism.</p>
<p>As therapy for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.</p>
<p>Amelioration of the severity of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to blood or plasma.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_s4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Carbinoxamine maleate is contraindicated in children younger than 2 years of age.</p>
<p>Carbinoxamine maleate is contraindicated in nursing mothers. </p>
<p>Carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (See <a href="#i4i_section_ID_s6.4">Drug Interactions</a> section.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_s5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products, therefore, carbinoxamine maleate is contraindicated in children younger than 2 years of age (see <a href="#i4i_contraindications_ID_s4">CONTRAINDICATIONS</a>).</p>
<p>Antihistamines should be used with considerable caution in patients with: narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span>, pyloroduodenal obstruction.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_s6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_s6.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with many other antihistamines, carbinoxamine maleate has an atropine-like action and, therefore, should be used with caution in patients with: <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, cardiovascular disease, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Antihistamines such as carbinoxamine maleate should not be used to treat lower respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_s6.2"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Carbinoxamine maleate may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; alcohol, sedatives, and tranquilizers may increase the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.4"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Monoamine oxidase inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. </p>
<p>Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_s6.6"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to determine the possible effects of carbinoxamine maleate on carcinogenesis, mutagenesis, and fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_s6.7"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_s6.7.1"></a><a name="section-6.5.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether carbinoxamine maleate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Carbinoxamine maleate should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_s6.9"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, use of carbinoxamine maleate is contraindicated in nursing mothers (see <a href="#i4i_contraindications_ID_s4">CONTRAINDICATIONS</a> section).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_s6.10"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see <a href="#i4i_contraindications_ID_s4">CONTRAINDICATIONS</a>).</p>
<p>Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_s6.11"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Carbinoxamine maleate is more likely to cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in elderly patients (approximately 60 years or older). Sedating drugs may also cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over sedation in the elderly. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_s7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent adverse reactions are underlined:</p>
<p><span class="Italics"><span class="Emphasis">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, excessive perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, dryness of mouth, nose and throat.</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>.</p>
<p><span class="Italics"><span class="Emphasis">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. </p>
<p><span class="Italics"><span class="Emphasis">Central Nervous System: </span></span><span class="Underline"><span class="Emphasis">Sedation</span></span>, <span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></span></span>, <span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></span></span>, <span class="Underline"><span class="Emphasis">disturbed coordination</span></span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, excitation, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, acute <span class="product-label-link" type="condition" conceptid="74052" conceptname="Labyrinthitis">labyrinthitis</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal: </span></span><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Epigastric distress</span></span></span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. </p>
<p><span class="Italics"><span class="Emphasis">Urogenital:</span></span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, difficult urination, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, early menses. </p>
<p><span class="Italics"><span class="Emphasis">Respiratory: </span></span><span class="Underline"><span class="Emphasis">Thickenings of bronchial secretions</span></span>, tightness of chest and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_s9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s9.1"></a><a name="section-8.1"></a><p></p>
<h2>Manifestations</h2>
<p class="First">Antihistamine over dosage reactions may vary from central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; fixed, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> may also occur.</p>
<p>Especially in infants and children, antihistamine overdosage may cause <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>The oral LD<span class="Sub">50</span> of carbinoxamine maleate in guinea pigs is 411 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s9.2"></a><a name="section-8.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">The treatment of overdosage with carbinoxamine maleate is essentially symptomatic and supportive. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_s10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see <a href="#i4i_contraindications_ID_s4">CONTRAINDICATIONS</a>). </p>
<p>Carbinoxamine maleate should be taken on an empty stomach with water.</p>
<p>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</p>
<p>Carbinoxamine maleate dosage should be based on the severity of the condition and the response of the patient. The drug is well tolerated in doses as high as 24 mg daily, in divided doses, over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>. On the other hand, some patients respond to as little as 4 mg daily.</p>
<p>Clinical experience suggests the following dosage schedules: </p>
<p><span class="Bold"><span class="Emphasis">Oral Solution:</span></span><br> Usual Adult Dosage:<br>   1 or 2 teaspoonfuls (4 to 8 mg)<br>   3 to 4 times daily</p>
<p>Usual Child’s Dosage (approximately 0.2 – 0.4 mg/kg/day divided into 3 to 4 doses):<br>   Six to eleven years – ½ to 1 teaspoonful (2 to 4 mg) 3 to 4 times daily.</p>
<p>Dosing for children 2 to 5 years of age should be based on weight whenever possible. The usual dosage for children 2 to 5 years of age is approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 daily doses. In general, this corresponds to a dose of ¼ to ½ teaspoonful (1 to 2 mg) 3 to 4 times daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_s11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Arbinoxa<span class="Sup">®</span> (Carbinoxamine Maleate) Oral Solution, 4 mg/5 mL is supplied as clear, colorless liquid with a bubble gum aroma, and is supplied in 16 oz bottles NDC 63717-871-16.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP controlled room temperature.] </p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s11.1"></a><a name="section-10.1"></a><p></p>
<h2>Manufactured for:</h2>
<p class="First">Hawthorn Pharmaceuticals, Inc.<br>Madison, MS 39110</p>
<p>Made in Canada</p>
<p>01/12          CW1876-1</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_ID_s20"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Bottle Label</h1>
<p class="First"> </p>
<div class="Figure">
<img alt="Arbinoxa, 473mL in 1 Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=040d6792-21fe-44cc-a441-b9693178b3b5&amp;name=f9ebe04a-39e2-4cfe-81d7-a692801dc334-02.jpg"><p class="MultiMediaCaption">Bottle Label</p>
</div>
<p><span class="Bold">NDC 63717-871-16</span></p>
<p><span class="Bold">Arbinoxa<span class="Sup">®</span><br>Oral Solution<br>(Carbinoxamine Maleate)</span></p>
<p><span class="Bold">4 mg/5 mL</span></p>
<p>Rx only</p>
<p>Hawthorn<br>Pharmaceuticals, Inc.</p>
<p>16 fl oz (473 mL)</p>
<p><span class="Bold">Description:<br></span>Each 5 mL (teaspoonful)<br>Contains:<br>Carbinoxamine<br>Maleate USP, 4 mg.</p>
<p><span class="Bold">Pharmacist:<br></span>Dispense in a tight,<br>light-resistant container<br>with a child-resistant<br>closure.</p>
<p><span class="Bold">Storage:<br></span>Store at<br>20° to 25°C<br>(68° to 77°F)<br>[See USP controlled<br>room temperature.]</p>
<p>HL216 01/12 CW1875-2</p>
<p><span class="Bold">Usual Dosage:<br></span>See package insert<br>for full prescribing<br>information.</p>
<p><span class="Bold">Warning:<br></span>Keep this and all<br>medication out of the <br>reach of children.</p>
<p>Manufactured for:<br>Hawthorn Pharmaceuticals, Inc.<br>Madison, MS 39110</p>
<p>Made in Canada</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ARBINOXA 		
					</strong><br><span class="contentTableReg">carbinoxamine maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63717-871</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBINOXAMINE MALEATE</strong> (CARBINOXAMINE) </td>
<td class="formItem">CARBINOXAMINE MALEATE</td>
<td class="formItem">0.8 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63717-871-16</td>
<td class="formItem">473 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090418</td>
<td class="formItem">04/01/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hawthorn Pharmaceuticals, Inc.
							(118049704)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Hawthorn Pharmaceuticals, Inc. (118049704)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f9ebe04a-39e2-4cfe-81d7-a692801dc334</div>
<div>Set id: 040d6792-21fe-44cc-a441-b9693178b3b5</div>
<div>Version: 3</div>
<div>Effective Time: 20120615</div>
</div>
</div> <div class="DistributorName">Hawthorn Pharmaceuticals, Inc.</div></p>
</body></html>
